Cited by 690Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 46 of the 51 references it cites were found in a registry or an index.

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Open access

Scagliotti, Giorgio, Hanna, Nasser, Fossella, Frank, Sugarman, Katherine, Blatter, Johannes, Peterson, Patrick, Simms, Lorinda, Shepherd, Frances A.·2009·The Oncologist

DOI 10.1634/theoncologist.2008-0232

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. METHODS: One study tested pemetrexed versus docetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (OS) and progression-free survival (PFS). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-adjusted between-arm hazard ratios (HRs). RESULTS: In both studies, treatment arms were well balanced for histology. THIs were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups. CONCLUSIONS: The consistency of these results across studies confirms the predictive effect of histology for pemetrexed and the survival advantage for pemetrexed in patients with nonsquamous histology. These analyses suggest pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, pemetrexed may be preferable to other agents for treatment of patients with nonsquamous NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2008-0232

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citation
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079

Flagged first, then by citations

Show all 51 references

5 of the 51 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Jiroutek, 1998, Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992, Proc Am Soc Clin Oncol, 17, 461a
National Cancer Institute, 1999, Common Toxicity Criteria v2.0 (CTC)

Sorted by citations

Items 601–687 of 687

Les CBNPC de stades avancés hors addiction oncogénique: les traitements systémiques de deuxième ligne
Pérol, M., Gauvain, C., Cortot, A. B., Souquet, P. J., Swalduz, A., & Avrillon, V. (2019) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(19)30105-3 · Cited by 1
Chemotherapy
Januszewski, A. P., & Popat, S. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10010514 · Cited by 1
Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101
Kawashima, Y., Ishimoto, O., Miyauchi, E., Sakakibara, T., Harada, T., Usui, K., Inoue, A., & Sugawara, S. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15076 · Cited by 1
Pathology of Adenocarcinoma
Travis, W. D. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch8 · Cited by 1
Refining the treatment of advanced nonsmall cell lung cancer
Wozniak, T., & Ogita (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s6075 · Cited by 1
Molecular tumor classification using a 92-gene assay in the differential diagnosis of squamous cell lung cancer
McGee, R. S., Kesty, N. C., Erlander, M. G., & Schnabel, C. A. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70059-1 · Cited by 1
Outpatient Chemotherapy for Non-small-cell Lung Cancer
Hirashima, T., Kondoh, Y., Tokuoka, Y., Morishita, N., Matsuura, Y., Tamiya, M., Suzuki, H., Sasada, S., Okamoto, N., & Kobayashi, M. (2011) · Haigan · doi:10.2482/haigan.51.113 · Cited by 1
Molecular subtypes of non-small-cell lung cancer
Stinchcombe, T. E. (2013) · doi:10.2217/ebo.12.201 · Cited by 1
First-Line Treatment and the New Paradigm of Histology-Based Treatment
Gridelli, C., Rossi, A., & Maione, P. (2013) · Springer eBooks · doi:10.1007/978-0-85729-793-8_14
Predictive biomarkers in diffuse gliomas and non-small cell lung cancer
Merkkiniemi, K. (2015) · Työväentutkimus Vuosikirja
Recurrent FISH abnormalities in solid tumors using paraffin‐embedded tissue
Zneimer, S. M. (2014) · doi:10.1002/9781118412602.ch32
Pathology of Lung Cancer
Beasley, M. B. (2011) · Medical radiology · doi:10.1007/174_2011_304
HIV and Lung Cancer
Okuma, Y., Yanagisawa, N., Hosomi, Y., Ajisawa, A., & Shibuy, M. (2011) · InTech eBooks · doi:10.5772/19974
Avaliação da custo-efetividade do tratamento do adenocarcinoma de pulmão avançado direcionado pela avaliação molecular do EGFR
Geib, G. (2012) · Americanae (AECID Library)
Változások a nem-kissejtes tüdőrák diagnosztikus és terápiás stratégiájában
Ostoros, G., Döme, B., Strausz, J., & Tímár, J. (2010) · Magyar Onkológia · doi:10.1556/monkol.54.2010.2.8
Die medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms
Heigener, D. F., Reinmuth, N., & Reck, M. (2015) · Der Pneumologe · doi:10.1007/s10405-015-0009-y
IL-22 in lavage as a biomarker in patients with lung cancer
Tufman, A. (2013) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.16428
Evolution of Therapy Decision-Making Process for Advanced Non-Small Cell Lung Cancer
Gebbia, V., Mancuso, G., Lombardi, L., & Maiello, E. (2009) · Oncology · doi:10.1159/000258501
Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study
Santoro, A., Hillerdal, G., Hoeffken, G., Favaretto, A. G., Carrion, R. P., Visseren‐Grul, C., Ameryckx, S., Helsberg, K., Soldatenkova, V., Bourayou, N., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.003
Controverse. Le traitement des CBNPC guidé par l’histologie : et si le critère choisi n’était pas le bon ?
Zalcman, G. (2009) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(09)72500-3
Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed
Dudek, A. Z., & Powell, S. F. (2009) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s3977
Traitements de 2e et 3e ligne : chimiothérapie ou TKI de l’EGFR ?
Bunel, V., & Greillier, L. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70529-4
Treatment of Non-Small Cell Lung Cancer: Focus on Pemetrexed Disodium
Feliciano, J. L., & Patel, J. D. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s5262
Unexpected Dramatic Response of Pretreated Invasive Thymic Malignancies on Pemetrexed-Case Report and Review of Current Treatment Modalities
Raman, P., & Surmont, V. F. M. (2012) · Open Journal of Respiratory Diseases · doi:10.4236/ojrd.2012.24016
Quoi de neuf dans les facteurs biologiques prédictifs de l’efficacité de la chimiothérapie ?
Zalcman, G. (2009) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(09)73436-4
Prise en charge des cancers bronchiques non à petites cellules au stade métastatique : évolution du traitement de première ligne
Pérol, M., Odier, L., & Arpin, D. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72513-3
Non-small cell lung cancer – ASCO 2009
Rothschild, S. I., & Gautschi, O. P. (2009) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-009-0160-4
Updating the 2011 International Association for the Study of Lung Cancer classification of Lung Adenocarcinoma: Main Priorities and Implications For Clinicians
Duhig, E., & Clarke, B. E. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.4
Carcinome bronchique non à petites cellules : quelle chimiothérapie de rattrapage ?
Duruisseaux, M., Sakhri, L., Toffart, A., & Moro‐Sibilot, D. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70599-3
Les outils biologiques en pratique : aide au diagnostic, au pronostic et au traitement du cancer bronchique
Mazières, J., Rouquette, I., & Brouchet, L. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72497-8
Trends among US oncologists in managing patients with nonsmall cell lung carcinoma: 2011-2013
Williamson, J., Aasen, H., Casebeer, L. L., Hayes, T. G., & Nevins, P. (2014) · Clinical Communications-Oncology · doi:10.4103/2393-8633.146105
Pemetrexed in Heavily Pretreated Non-Small-Cell Lung Cancer Patients: Case Report and Review of the Literature
Tartarone, A. (2010) · Future Oncology · doi:10.2217/fon.10.146
Is there a role for maintenance therapy in advanced non-small-cell lung cancer?
Gridelli, C., Maione, P., Rossi, A., Schettino, C., Bareschino, M. A., Sacco, P. C., Palazzolo, G., Casaluce, F., Sgambato, A., & Ciardiello, F. (2012) · Clinical Practice · doi:10.2217/cpr.11.126
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Pallis, A. G., Dziadziuszko, R., & O'Brien, M. E. R. (2013) · Clinical Investigation · doi:10.4155/cli.13.6
Pemertrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer: a case report and literature review
Zhao, C., Hu, F., Zhang, G., Yuan, J., & Zhang, W. (2012) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-011-0900-x
Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
Hirsh, V. (2009) · Journal of Lung Cancer · doi:10.6058/jlc.2009.8.2.61
Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore.
Lopes, G. D. L., Jr., Chopra, A., Kukutschka, J., Portillo, P., Bharwani, L. D., & Chang, A. (2011) · PubMed
The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes
Sgambato, A., Casaluce, F., Rossi, A., Maione, P., Sacco, P. C., Ciardiello, F., & Gridelli, C. (2015) · Clinical Investigation · doi:10.4155/cli.14.121
The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example
Li‐Wan‐Po, A., Farndon, P. A., Kobayashi, S. S., Mitsudomi, T., & Potter, V. A. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p496
DISCOVERY AND VALIDATION OF PROTEIN BIOMARKERS FOR LUNG CANCER
Petris, L. D. (2010) · Figshare
MAintenAnce therApy in Adv Anced non-sMAll cell lung cAncer Does emerging evidence support its use?
Tsang, R. Y., & Butts, C. A. (2009)
Traitements de rattrapage du cancer bronchique non à petites cellules
Plat, G., & Mazières, J. (2011) · Springer eBooks · doi:10.1007/978-2-287-99041-0_10
Lung Cancer in Older Patients
Gettinger, S. N., & Tanoue, L. T. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-727-3_5
The evolving role of molecular diagnosis of cancer types and subtypes: stay tuned
Greco, F. A. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70060-8
A Case of Squamous Cell Carcinoma of the Lung Diagnosed During Long Term Pemetrexed Chemotherapy for Recurrent Large Cell Carcinoma of the Lung
Katono, K., Kimura, M., Ryuge, S., Igawa, S., Yanase, N., & Masuda, N. (2013) · Haigan · doi:10.2482/haigan.53.29
A Case of Drug-induced Interstitial Pneumonia Due to Pemetrexed
Fujita, Y., Hirano, S., Takeda, Y., Sugiyama, H., Kobayashi, N., & Kudo, K. (2011) · Haigan · doi:10.2482/haigan.51.237
Maintenance Chemotherapy for Advanced Non-small-cell Lung Cancer
Gadgeel, S. M. (2010) · European Oncology & Haematology · doi:10.17925/eoh.2010.06.1.47
Squamous cell carcinoma of the lung
Flieder, D. B., & Brambilla, E. M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139018760.031
Second-line therapy of non-small cell lung cancer
Heigener, D. F., Bohnet, S., & Reck, M. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.008
Personalized Management of Lung Cancer
Komaki, R. R. (2013) · doi:10.2217/9781780842165
First-line therapy of advanced non-small cell lung cancer not harboring an activating EGFR mutation
Gridelli, C., & Rossi, A. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.006
The Use, Effectiveness, and Safety of Bevacizumab In Older Adults With Advanced Stage Non-Small Cell Lung Cancer
Katz, A. J. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/praa-m387
Continuation maintenance therapy with pemetrexed in patients with non-small-cell lung cancer in the Czech Republic
Skřičková, J., Fröhlich, K., Kuhn, M., Bortlíček, Z., Hejduk, K., Pešek, M., Kolek, V., Grygárková, I., Koubková, L., Černovská, M., et al. (2016) · Onkologie · doi:10.36290/xon.2016.008
Advancing the Management of Non-small Cell Lung Cancer
Fakih, D. F. (2017) · European Oncology & Haematology · doi:10.17925/eoh.2017.13.01.53
Review Article Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies
Wang, Z. (2014)
Cancer bronchique non à petites cellules de stade IV sans addiction oncogénique : traitements en 2e ligne et au-delà
Gauvain, C., & Cortot, A. B. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30057-5
Are Second- and Third-Line Treatments in the Elderly Feasible?
Gridelli, C., Rossi, A., & Maione, P. (2013) · Springer eBooks · doi:10.1007/978-0-85729-793-8_16
Efficacy and safety of pemetrexed and cisplatin chemotherapy as first line in advanced stage of lung adenocarcinoma.
Jain, K., Bapna, A., Somani, N., Sharma, L. M., & Aggarwal, P. (2018) · doi:10.35841/molecular-oncology.2.3.68-73
Systemic Options for Second-Line Therapy and Beyond
Goss, G. D., & Mok, T. S. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00045-7
Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC).
Farooq, A., Dy, G. K., Demmy, T. L., Bogner, P. N., Nowadly, C., Tan, W. C. C., Chen, H., Yendamuri, S. S., Nwogu, C. E., Bushunow, P. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e17535
Lessons for Precision Medicine from Lung Cancer
Bade, B. C., Foley, F., & Tanoue, L. T. (2020) · Respiratory medicine · doi:10.1007/978-3-030-31507-8_14
A comparative analysis of P40 and P63 immunomarkers for differentiation of squamous cell carcinoma and adenocarcinoma, lung
Jamil, S. F., Fauzdar, M., Agarwal, M., & Gupta, S. (2020) · International Journal of Clinical and Diagnostic Pathology · doi:10.33545/pathol.2020.v3.i1c.172
Lung Cancer
Erasmus, J. J., Stewart, D. J., Komaki, R. R., & Swisher, S. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2232-1.00006-1
Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne
Scherpereel, A., Pérol, M., Gauvain, C., Cortot, A. B., & Leprieur, E. G. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30099-9
The role of the immunohistochemical marker p40 in the differential diagnosis of adenocarcinoma and nonkeratinizing squamous cell cancer of the lung
Olyushina, E. M., Byakhova, M. M., Эдуардовна, З. Л., Andreeva, Y. Y., Semenova, A. B., & Франк, Г. А. (2020) · Russian Journal of Archive of Pathology · doi:10.17116/patol20208205150
Formulation of targeted drug-loaded nanoparticles for lung cancer therapy
Jailani, M. T. M. (2020)
Inmunoterapia en el cáncer de pulmón
Casado, D. I., Bellido, L., del Barco, E., Cigarral, B., Escalera, E., Claros, J., Barrios, B., Figuero, L., Olivares, A., López, Á., et al. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.02.009
Identification of Gene Markers for Survival Prediction of Lung Adenocarcinoma Patients Based on Integrated Multibody Data Analysis
Bao, Y., Luo, J., Yu, T., Liu, Y., Li, X., Lin, Q., & Wang, H. (2021) · Journal of Nanomaterials · doi:10.1155/2021/9997939
Definition of “Tissue-Based Biomarker,” its Place in Medicine, and Molecular Pathology
Sağol, Ö., & Sarıoğlu, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-84432-5_1
Current World Literature
(2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328344b687
First-line therapy
Gauthier, M.-P., & Leighl, N. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-69573-2.00017-6
Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne
Leprieur, E. G., Scherpereel, A., Pérol, M., Gauvain, C., & Cortot, A. B. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00142-8
Treatment of Stage IV Non-small Cell Lung Cancer
Sun, T. Y., & Das, M. S. (2023) · Respiratory medicine · doi:10.1007/978-3-031-38412-7_8
Therapy with ALK-positive non-small cell lung cancer: reality and prospects
Breder, V. V., Лактионов, К. К., Yudin, D. I., & Хамрина, Н. Е. (2014) · Russian Journal of Oncology · doi:10.17816/onco40081
Use of Novel National Data Sets to Monitor Chemotherapy Use and Outcomes: A Retrospective Cohort Study of Non–Small-Cell Lung Cancer in Aotearoa New Zealand
Minhinnick, A., Dunn, A., Arabnejad, V., Paddison, J. S., Jackson, C., Pointer, S. M., Gurney, J., & Cameron, L. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00483
Fifteen years of precision medicine in the lung cancer management: Perspectives and Challenges
Ferreira, C. G., Marchi, P. D., Veloso, G. G. V., Reis, M. X., Barcelos, I. F., & Montella, T. C. (2024) · Medical Research Archives · doi:10.18103/mra.v12i2.5169 · Cited by 2
EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report
Martínez-Hernandez, M. F., Lara‐Mejía, L., Izquierdo-Tolosa, C., Cabrera-Miranda, L. A., & Arrieta, O. G. (2024) · Oncology Research and Treatment · doi:10.1159/000541496
Renal dysfunction during osimertinib treatment in patients with non–small cell lung cancer positive for EGFR mutations
Miyazaki, Y., Iwama, E., Ogata, H., Ibusuki, R., Shibahara, D., Otsubo, K., Shiraishi, Y., Yoneshima, Y., Torisu, K., & Okamoto, I. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.03.015
ACOT11 as a novel biomarker and therapeutic target in lung squamous cell carcinoma
Liu, C., Wang, Y., Tang, M., & Zhang, Y. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.08.229
The tear film protein profile in blepharitis
Muttuvelu, D. V. (2025) · Acta Ophthalmologica · doi:10.1111/aos.16762
Additional file 1 of Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data
Taniguchi, Y., Okamoto, H., Shimokawa, T., Sasaki, T., Seto, T., Niho, S., Ohe, Y., & Saigusa, Y. (2022) · Figshare · doi:10.6084/m9.figshare.18094488
Additional file 1 of Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis
Carroll, R., Bortolini, M., Calleja, A., Munro, R. E. J., Kong, S., Daumont, M. J., Penrod, J. R., Lakhdari, K., Lacoin, L., & Cheung, W. Y. (2022) · Figshare · doi:10.6084/m9.figshare.19336230
Actualités et synthèse du traitement de seconde ligne des CBNPC de stade IV sans addiction oncogénique
Pierret, T., Descourt, R., Corre, R., Tomasini, P., & Decroisette, C. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.02.003
A prospective diffusion-weighted MRI study for differentiation of squamous cell carcinoma and adenocarcinoma in lung cancer
Youssef, S. M. H. A., Nasr, M. A., Afifi, M., & Tawfik, S. M. (2026) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-026-01767-3
Treatment sequence after first-line immunotherapy in older adults with advanced NSCLC (NEJ057)
Kushiro, K., Tsukita, Y., Tozuka, T., Hosokawa, S., Sumi, T., Uematsu, M., Honjo, O., Yamaguchi, O., Kyoyama, H., Tsurumi, K., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03206-9
Antimetabolites
Al-Modaris, I. F. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch003
How to Personalize Perioperative Chemotherapy in Early Non-small Cell Lung Cancer?
Carnio, S., Bironzo, P., Novello, S., & Scagliotti, G. V. (2014) · Springer eBooks · doi:10.1007/978-3-319-06062-0_5
Self-citation

Authors: Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A.
Affiliations: University of Turin (IT)
Indiana University Indianapolis (US)
The University of Texas MD Anderson Cancer Center (US)
Eli Lilly (United States) (US)
Eli Lilly (Germany) (DE)
Eli Lilly (Canada) (CA)
University of Toronto (CA)
Corresponding author: Scagliotti, Giorgio
ORCID: Scagliotti, Giorgio
Hanna, Nasser
Peterson, Patrick
Shepherd, Frances A.
Venue: The Oncologist
Publisher: Oxford University Press (OUP)
Published: 2009-02-16
Volume: 14
Issue: 3
Pages: 253-263
ISSN: 1083-7159 (ISSN-L)
1549-490X
DOI: 10.1634/theoncologist.2008-0232
OpenAlex: W2139939379
Cited by: 690
References: 51
Citations by year: 2026: 5 · 2025: 8 · 2024: 10 · 2023: 15 · 2022: 21 · 2021: 15 · 2020: 27 · 2019: 29 · 2018: 30 · 2017: 42 · 2016: 46 · 2015: 41 · 2014: 69 · 2013: 72 · 2012: 71
FWCI: 72.97
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: The Oncologist (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: pemetrexed, non-small cell lung cancer, tumor histology, squamous cell carcinoma, docetaxel, overall survival, progression-free survival, predictive biomarkers
MeSH terms: Pemetrexed, Docetaxel, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Randomized Controlled Trials as Topic, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks